Acoltremon - Alcon
Alternative Names: AR-15512; AVX 012; WS-12Latest Information Update: 31 Oct 2024
Price :
$50 *
At a glance
- Originator Instituto de Neurociencias de Alicante
- Developer Alcon; AVX Pharma
- Class Cyclohexanes; Ethers; Eye disorder therapies; Small molecules
- Mechanism of Action TRPM8 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 28 Oct 2024 Alcon plans a phase III trial for Dry eyes (Topical, Drops), in January 2025 (NCT06660290)
- 15 Oct 2024 Alcon initiates enrollment in a phase IIIb trial for Dry eyes (Ophthalmic, Drops) in USA (NCT06544707)
- 08 Oct 2024 Alcon research initiates a phase III trial for Dry eye disease in the US (Ophthalmic) (NCT06544694)